Diabetes Drug R&D Services ace

Inquiry

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest FETUIN-A-Targeted Antidiabetic Drug Development Services
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

FETUIN-A-Targeted Antidiabetic Drug Development Services

FETUIN-A contributes to insulin resistance by promoting free fatty acid transport, triggering β-cell inflammation, and inhibiting insulin receptor autophosphorylation, while its gene knockout enhances insulin sensitivity. Thus, FETUIN-A represents a promising therapeutic target for antidiabetic drug development. Ace Therapeutics offers comprehensive antidiabetic drug development services targeting FETUIN-A. We provide end-to-end solutions from target validation to preclinical evaluation. Leveraging specialized diabetic animal models and advanced metabolic analysis platforms, we deliver integrated solutions including in vitro activity screening, in vivo efficacy assessment, pharmacokinetic studies, and safety evaluation.

FETUIN-A as an Antidiabetic Drug Target

Fetuin-A is an important protein required for carrying free fatty acids (FFA) to the circulation and involved in the inflammation of the β-cells and can lead to β-cell deterioration in the pancreas thus causing insulin resistance and some other metabolic disorders. Fetuin-A inhibits the autophosphorylation of the tyrosine kinase, one of the main enzymes in insulin signaling, which directly opposes insulin action. There is the major interface among insulin and tyrosine kinase to balance the blood glucose in the system and if the concentration of the Fetuin-A will increase in the blood then the insulin resistance may occur in the body and ultimately diabetes. Studies revealed that there is an increase in the insulin sensitivity in mice which are having Fetuin-A knockout genes in them which shows the negative relation of the Fetuin-A with insulin sensitivity in diabetes. These above listed factors indicate that Fetuin-A is an innovative target for the management of diabetes mellitus.

The involvement of Fetuin-A in diabetes and related metabolic disorders. Fig. 1 Role of Fetuin-A diabetes and other metabolic disorders. (Dhankhar, S.; et al., 2023)

FETUIN-A-Targeted Antidiabetic Drug Development Services at Ace Therapeutics

Ace Therapeutics, as a preclinical contract research organization specializing in diabetes, provides antidiabetic drug development services targeting FETUIN-A. Leveraging customized diabetes models and an established metabolic disease research platform, we empower clients to develop novel FETUIN-A-targeting antidiabetic therapeutics. Building on our profound mechanistic understanding, we offer the following core services:

Services	Description
FETUIN-A inhibitor screening services	Through structural biology-guided molecular design, we help our clients screen small molecule/antibody candidates that specifically block FETUIN-A binding to the insulin receptor.
In vivo and in vitro efficacy evaluation services	In vitro: Insulin receptor tyrosine kinase phosphorylation assay and β-cell survival rate evaluation. In vivo: Systemic evaluation of drug effects on glycemic homeostasis and pancreatic pathological alterations in HFD/STZ-induced models and db/db mice.
Preclinical safety assessment	Toxicological profiling Metabolic safety assessment Cardiometabolic risk evaluation Immunotoxicity assessment

Advantages of Our FETUIN-A-Targeted Antidiabetic Drug Development Services

Mechanism-driven drug discovery: Based on the core mechanism of action of FETUIN-A in insulin resistance, our advanced R&D platform can efficiently screen drug candidates with clear targets of action and improve the success rate of antidiabetic drug development.
Comprehensive in vivo & in vitro models: Including FETUIN-A overexpression/knockout cell models, primary cell models from insulin-target tissues (liver/adipose/muscle), and spontaneous/induced diabetic animal models.
Comprehensive endpoint coverage: Integrated analysis spanning molecular-level assessments (tyrosine kinase phosphorylation) to systemic metabolic evaluations (continuous glucose monitoring, hyperin sulinemic-euglycemic clamp technique).

Ace Therapeutics is dedicated to providing professional antidiabetic drug development services targeting FETUIN-A. Our featured services include FETUIN-A specific inhibitor development, functional analysis of insulin signaling pathways, and validation of animal models of diabetes to help clients accelerate the development of novel antidiabetic drugs. For detailed service solutions, please feel free to contact our expert team for customized service proposals.

Reference

Dhankhar, S.; et al. Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology & Metabolic Syndrome. 2023, 15(1): 17.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services